Variation in Quality of Post-Surgery Cancer Care
Nov 2, 2018
A study of more than 350 hospitals found variations in readmission and mortality rates after cancer surgical procedures.
Cancer Management
Head and Neck Tumors
Jun 2, 2016
This management guide covers the risk factors, symptoms, diagnosis, staging, and treatment of head and neck cancers (including tumors of the oral cavity, oropharynx, hypopharynx, larynx, supraglottis, glottis, subglottis, and nasopharynx) using radiation, surgery, and medical treatment.
Soft-Tissue Sarcomas
Jun 2, 2016
The soft-tissue sarcomas are a group of rare but anatomically and histologically diverse neoplasms. This is due to the ubiquitous location of the soft tissues and the nearly three dozen recognized histologic subtypes of soft-tissue sarcomas.
Long-Term Central Venous Access
Jun 2, 2016
The use of multidrug chemotherapy and bone marrow transplantation in cancer treatment has made the utilization of reliable, long-term venous access (LTVA) an essential component of cancer therapy. The placement of LTVA devices not only permits the delivery of these complex therapeutic regimens but also drastically improves patients’ quality of life.
Chemotherapeutic Agents and Their Uses, Dosages, and Toxicities
Jun 2, 2016
This list of chemotherapeutic agents covers the cancers each drug is used for, as well as the recommended dosage and possible toxicities of the therapy.
Non-Small-Cell Lung Cancer
Jun 1, 2016
This management guide for non–small-cell lung cancer (NSCLC) covers the symptoms, screening, diagnosis, staging, and treatment of adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma of the lung.
Thyroid and Parathyroid Cancers
Jun 1, 2016
This management guide of endocrine malignancies covers the risk factors, diagnosis, screening, and treatment of both thyroid and parathyroid cancers.
Myeloproliferative Neoplasms
Jun 1, 2016
Myeloproliferative neoplasms are a group of clonal myeloid cell–derived disorders characterized by myeloproliferation without dysplasia, bone marrow hypercellularity, and predisposition to thrombosis, hemorrhage, and bone marrow fibrosis.
Response Evaluation Criteria and Performance Scales
Jun 1, 2016
In clinical studies, formal response criteria have been developed and have gained wide acceptance. The National Cancer Institute (NCI) has proposed and implemented newer standard response criteria called Response Evaluation Criteria in Solid Tumors (RECIST). In contrast, the World Health Organization (WHO) has a different standard for assessing response. Major differences between these guidelines are outlined below.
Ovarian Cancer
Jun 1, 2016
Despite the fact that it is highly curable if diagnosed early, ovarian cancer causes more mortality in American women each year than all other gynecologic malignancies combined.
